SCHEMBL16748596

SCHEMBL16748596

Nc1nc(Nc2ccc(Cl)cc2)nc(-n2c(C3CC3)nc3c(F)cccc32)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.38
MAPT P10636 3/20 0.38
HTT P42858 2/20 0.38
ADORA3 P0DMS8 1/20 0.36
SLC6A2 P23975 1/20 0.36
PDE4A P27815 1/20 0.36
KDR P35968 1/20 0.36
ALDH1A1 P00352 5/20 0.36
USP2 O75604 2/20 0.36
BMI1 P35226 5/20 0.35
AGPAT2 O15120 2/20 0.34
CDK9 P50750 1/20 0.34
GBA1 P04062 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.33
ALOX12 P18054 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748447 0.90 BMI1 (0.35) MAPTHTTALDH1A1USP2BMI1
SCHEMBL16740853 0.90 HTT (0.43) MAPK1MAPTHTTALDH1A1USP2
SCHEMBL16748499 0.89 BMI1 (0.47) MAPTBMI1
SCHEMBL16740797 0.88 BMI1 (0.47) MAPK1MAPTALDH1A1BMI1KDM4E
SCHEMBL16748502 0.86 BMI1 (0.49) MAPTBMI1
SCHEMBL16740742 0.84 BMI1 (0.47) MAPK1MAPTHTTADORA3SLC6A2
SCHEMBL16740820 0.84 ADORA3 (0.39) MAPK1MAPTHTTADORA3SLC6A2
SCHEMBL16740819 0.82 BMI1 (0.38) ALDH1A1USP2BMI1NPSR1HPGD
SCHEMBL16740774 0.81 AGPAT2 (0.39) MAPK1MAPTHTTADORA3SLC6A2
SCHEMBL16748418 0.80 BMI1 (0.42) MAPK1MAPTHTTADORA3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B MAPK1 1302/4885MAPT 4579/4885HTT 4137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.